chrisvoncsefalvay/vaers-outcomes huggingface dataset:
change in taste/ taste was not right/ can't taste salt/ everything tastes bland; This spontaneous case was reported by a consumer and describes the occurrence of TASTE DISORDER in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031M20A and 001B21A) for COVID-19 vaccination.     Concurrent medical conditions included Grass allergy, Cervical spinal stenosis (C2/C3), Allergy to molds, and Allergy to animal.   On 10-Feb-2021 at 3:45 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021 at 8:45 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Mar-2021, the patient experienced TASTE DISORDER. On 17-Mar-2021, TASTE DISORDER had resolved.            No relevant concomitant medications were provided.  The patient reported that nine to ten hours after second shot, the patient noticed that foods did not taste same. According to the patient, taste was not right. The patient couldn't taste it on chips, eggs, oatmeal, and everything tasted bland. The patient stated that he had similar thing happen when he ate pineapple (lasted 2-3 hours). The sense of smell did not seem to be affected. Within several days, the symptoms disappeared, and normal taste resumed. The patient did not receive treatment.   Most recent FOLLOW-UP information incorporated above includes: On 31-May-2021: Additional information received included patient initials and demographic details, Medical history, Vaccination information including lot#, and additional description of event including outcome.
This spontaneous report as received from an unknown age male patient refers to himself. On an unknown date in November 2012 the patient was vaccinated with a dose of ZOSTAVAX (lot #, expiration date, route not reported) for prevention of shingles. On an unknown date the patient experienced shingles. The patient was treated with unspecified medications. The patient sought medical attention via office visit on an unknown date. The outcome of the event was unknown. Additional information has been requested.
Pt recv vax on 11/17/98; on 11/18/98 pt exp unconsolable crying  > 3 hr, fussy x 3-4 days
Client complained of nausea and light-headedness after receiving the vaccine.  Client states history of needle phobia with this type of reaction.  Fire Rescue assessed patient.   Patient released at 9:42am per fire rescue no further evaluation needed.
Left leg had small area of redness & swelling at injection site. Pt had low grade fever and was very fussy.
Patient returned to the pod at 1219 after receiving her vaccine at 1201.  pt states when she got to her car she began to feel dizzy and lightheaded. pt is also now having heart palpitations.  no shortness of breath. no other symptoms. pt was assessed and vitals taken. bp is elevated at 189/120. all other vitals normal. additional rig was called for transport at 1243 due to rig on scene being dedicated to the standby. pt was further treated with an iv 20 gauge saline lock left forearm, and a 4 and 12 lead on the cardiac monitor. pts 12 lead showed a sinus rhythm with right bundle branch block. pt states she has no cardiac hx. kunkel medic 6 arrived at apprx 1255 and transported her to at 1300.
Pt fainted within a couple of minutes of administration of vaccine. Pt was brought back to seat after falling. (Did not hit head). Pt was awake but sweating profusely, dizzy and sleepy. Pt was given water to drink, wiped with a wet towel and fanned down. After 25 min. pt was feeling much better and was able to leave with family.
Rheumatoid factor elevated at 45, CRP 122  Patient was in good health, with distant history of Graves Disease until April 5 when he presented to Hospital with complaints of chest pain, worse with sitting up.  CAD was ruled out with troponins and he was taken to the cath lab and found to have essentially normal coronary arteries.  He was started on colchicine with improvement in chest pain.  On April 30th he presented to Hospital with low grade temps, cough and right sided chest/abdominal pain.  He was found to have moderate pleural effusion.  Because he was on Eliquis, for episode of afib thought related to pericarditis, pleurocentesis was delayed until May 3 when 1.5 L of fluid was removed from his pleural space.  He continued on colchicine and 3 days later reported feeling essentially normal.  Blood and fluid cultures were negative.  Pleural fluid cytology showed predominantly chronic, inflammatory lymphocytes and macrophages/monocytes, reactive mesothelial cells.  There was no overt morphologic evidence of malignancy.   Patient was feeling well.  Dr stopped Eliquis, Cochicine and patient did well until May 17 when he again reported aches, chills and pleuritic chest pain.  Pleural effusion recurred and patient restarted cochicine with improvement
Pt. is a 19 month old ex-25 week preemie, normally developing for gestation. S/P grade IV bilat IVH at birth. Behind imz; vaccine listed below provided 9/21/15-high fever, 104 degrees within 6 hours with tonic, but not clonic seizure, lasted <5 min. Hospitalized x 4 days.
uncomfortable; This case was reported by a consumer via (Shingrix chat boot) interactive digital media and described the occurrence of discomfort in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On 28th September 2021, the patient received Shingrix. In September 2021, less than a day after receiving Shingrix, the patient experienced discomfort. On an unknown date, the outcome of the discomfort was unknown.   It was unknown if the reporter considered the discomfort to be related to Shingrix.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The reporter said he/she just had the vaccine yesterday from the day of reporting and felt uncomfortable all day and night. The follow-up would not possible as no contact details were available. The case had been linked with US2021AMR205346 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR205346:same reporter
Migraine; This is a spontaneous report from a contactable consumer (patient) via a Pfizer-sponsored program, . This female patient of unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; lot number unknown) via an unspecified route of administration on 11Apr2021 as a singe dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient reported she had her first dose on 11Apr2021, and her second dose was scheduled "today" (as of 02May2021). She reported experiencing a migraine and was not sure if it was okay to take the second dose. The clinical outcome of migraine was not recovered.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Approximately one hour after vaccine administration, pt c/o numbness and tingling of R cheek and jaw along with numbness and tingling of R shoulder extending to R elbow. Symptoms disappeared post 24 hours.
knots within the palms of their left hand; This spontaneous case was reported by a consumer and describes the occurrence of DUPUYTREN'S CONTRACTURE (knots within the palms of their left hand) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 027L20A) for COVID-19 vaccination.     Concurrent medical conditions included COVID-19 since 29-Dec-2020.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DUPUYTREN'S CONTRACTURE (knots within the palms of their left hand) (seriousness criterion medically significant). At the time of the report, DUPUYTREN'S CONTRACTURE (knots within the palms of their left hand) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Dec-2020, SARS-CoV-2 test: positive (Positive) Positive.         No concomitant medications were provided by the reporter.  Treatment information was not provided by the reporter.  Company Comment: Very limited information regarding this event has been provided at this time. Additional information required.; Sender's Comments: Very limited information regarding this event has been provided at this time. Additional information required.
Information has been received from a registered nurse concerning a healthy 43 year old white female phlebotomist, with allergies to sulfa, cimetidine (TAGAMET) and acetaminophen (+) oxycodone (PERCOCET), who on 18-JUL-2005, at 3:30 PM, was vaccinated with a first subcutaneous dose in the right arm of varicella virus vaccine live (Lot# 9376606). There was no concomitant medication. There was no illness at the time of vaccination and no adverse events following prior vaccination. It was noted that the patient had a varicella titer prior to vaccination 18-JUL-2005 and it was less than 0.91. On approximately 05-AUG-2005 or 07-AUG-2005, the patient experienced a generalized rash and malaise. Unspecified medical attention was sought. The outcome was reported as recovering. There was no product quality complaint. Follow-up information from a health professional indicated that on 07-AUG-2005, in the AM, the patient developed a generalized skin rash, described as being similar to chickenpox. The patient was treated with acyclovir. Follow-up information from a health professional indicated that on 22-AUG-2005 the patient recovered. Additional information is not expected.
Information has been received from a registered nurse concerning a 19 year old female patient with asthma and penicillin allergy which caused breath shortness and hives and with no illness at time of vaccination, who on 04-AUG-2008 at 15:10 was vaccinated with 0.5 mL of VARIVAX vaccine (Merck) (Lot #660402/0271X) SQ in the left upper arm. Concomitant therapy was not reported. On 13-AUG-2008 at 12:30 pm, nine days post subcutaneous vaccination, the patient experienced tenderness in the administered site. The reporter stated that the patient had difficulties with sleep that the previous night and also reported a patient's headache and generalized achiness. The patient developed a 4-5 cm indurated erythema area into the left medial aspect of left upper extremity, it was warm to touch with faint blue tinged approximately 1 cm surrounding area. She experienced pain and itching in the left medial aspect upper extremity, approximately a hand, breadth under left acromion process. The reported stated that on 14-AUG-2008 the patient developed signs and symptoms late night at 23:30, nine days post injection, the patient had signs and symptoms similar to insect sting/bite. The registered nurse stated that the patient recently sprayed the house and did not think it was an insect. The reporter called the pharmacist who stated that she did not think it was the vaccine related with the incident. Also, the reporter spoke with other registered nurse who also stated she did not think it was vaccine related. On 05-SEP-2008, the patient was vaccinated with the second dose of 0.5 mL of VARIVAX vaccine (Merck) SQ, without any difficulty but had a previous incident thought to have been an insect sting. The registered nurse suggested to follow up with the primary care physician for the signs and symptoms of infection, purulent drainage, worsening pain, tissue necrosis, systemic symptoms and signs of fever. The patient stated that she was used an over the counter medication, cortisol cream, for symptoms management. On 18-AUG-2008, the patient recovered. The patient did seek medical attention at office visit. Additional information is expected.
Robust reaction.  Mild tender axillary nodes.  Vesico-papular rash left upper extremity (approximately 10 lesions) with 3 lesions on back.  Present for two days.  No accompanying fever.  Temp today is 98.4 and otherwise well.
One week after receiving the vaccine, I started having a chemical smell 24/7 that no one else can smell. It?s been over a week now and the smell continues to be a problem 24/7 for me. It started in the middle of the night while I was getting ready for bed.
Pain in the upper outer right thigh. It does not feel muscular. (It feels like my bone hurts.)
patient reported burning sensation when dose was administered.  said she ecxperienced burning for several days afterwards and ahas felt a lingering soreness in her arm for the 2 months since injection
This event occurred 9 days post 2nd Moderna vaccine. I also had a delayed reaction after the first dose documented on v-safe.  On 2/2/21:  symptoms included fatigue, chills, and fever and night sweats and increase in sleep time.  These symptoms also occurred on the day following the 2nd dose. As on the day following the 2nd dose,   I self medicated on the evening of 2/2 with one ibuprofen/acetaminophen (125mg/250mg) tablet .   No significant symptoms on waking on 2 / 3 / 21 other than mild fatigue.
headache, right and left upper arm muscle ache, no appetite or energy  lasted 24 hours
This spontaneous report as received from a medical assistant refers to an unspecified number of patients of unknown age and gender. Between 09-NOV-2015 and 12-NOV-2015, the patients were vaccinated with improperly stored doses of oral, ROTATEQ lot # L008574 exp 22-NOV-2016, (route and dose were not provided). This is one of several reports received from the same reporter. Additional information has been requested.
hives on inside of both arms;welts about 12hr p/vax;cold compress used;gone w/in 8hr;
received first dose of COVID vaccine on 18Dec2020 and tested positive on 30Dec2020; received first dose of COVID vaccine on 18Dec2020 and tested positive on 30Dec2020; she had a 5 day migraine after the first dose; This is a spontaneous report from a contactable other healthcare professional (patient). A female patient of an unspecified age started to receive BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Solution for injection (lot number and expiry date were unknown), via an unspecified route of administration on 18Dec2020 at first single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient received first dose of COVID vaccine on 18Dec2020 and tested positive on 30Dec2020. The patient stated her isolation will be over the day that she was to receive her second dose. The patient stated that she had a 5-day migraine after the first dose. Outcome of the events was unknown.  Information on the lot/batch number has been requested.  Follow-up (06Jan2021): New information received in response to query via mail includes confirmation of the primary reporter's last name.  Information on the lot/batch number has been requested.; Sender's Comments: Based on the information currently available, a lack of efficacy with the suspected vaccine BNT162B2 in this patient cannot be completely excluded.  Further information like confirmative virus genome /nucleic acid detection needed for meaningful medical assessment.
tired; achy; This is a spontaneous report received from a contactable reporter(s) (Other HCP).  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FATIGUE (non-serious), outcome "recovered", described as "tired"; PAIN (non-serious), outcome "recovered", described as "achy". Additional information: The reporter was a retired nurse, patient is her sister. The reporter was discussing medical history when she mentioned family and friends. The reporter stated that her kids and son-in-law and sister and friends got the Pfizer Covid-19 Vaccine too and got one day of being tired and achy and then bounced back to normal. Report 3 was caller reporting on her sister. The reporter did not want to file a report. The reporter stated that these people did not really have problems other than the expected things. One had a slight headache, one was tired, one had a temperature of 100. The reporter had nothing really to speak of. The reporter did not distinguish which person had which symptom, and does not provide any additional identifiers. No additional information provided.No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
retinal edema; macular edema; macular pucker; neuralgia; Information has been received from a lawyer regarding a case in litigation concerning the currently approximately 72 years old patient (pt) of unknown gender. On or about 14-JUN-2012, the pt was administered the zoster vaccine live (ZOSTAVAX) (route, dose, lot number and expiration date were not reported) for the long-term prevention of shingles and zoster-related conditions. Subsequently, the pt was treated by a provider for the following injuries resulting from the pt's zoster vaccine live (ZOSTAVAX) use: neuralgia, retinal edema, macular edema and macular pucker. The outcome of the events was not reported. The lawyer considered the events to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, retinal edema, macular edema and macular pucker were determined to be medically significant.
No adverse symptoms; The patient was vaccinated with PEDVAX on 31-JUL-2019, 25-SEP-2019, and 04-NOV-2019. Nurse stated an unspecified medical assistant, who vaccinated the patient, got the dosing schedule for PEDV AX confused with the dosing schedule for ACTHIB; This spontaneous report as received from a nurse who referred to a patient of unknown age, gender, and ethnicity. No information on patient's pertinent medical history, concomitant medications, and drug reactions or allergies was provided.  On 21-JUL-2019, the patient was vaccinated with a first dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (strength, dose, lot#, expiration date, and route of administration were not provided) as prophylaxis. The patient was vaccinated with a second and third dose of haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) (strength, dose, lot#, expiration date, and route of administration were not provided) as prophylaxis, on 25-SEP-2019 and 04-NOV-2019, respectively (inappropriate schedule of product administration). It was reported that an unspecified medical assistant, who vaccinated the patient, got the dosing schedule for haemophilus b conjugate vaccine (meningococcal protein conjugate) (LIQUID PEDVAXHIB) confused with the dosing schedule for Hib conj vaccine (tet toxoid) (ACTHIB). No adverse symptoms were reported.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 66-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Nov2021 as dose number unknown (booster), single (Lot number: 32030bd) at the age of 65 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment of COVID-19; (16Oct2022) Negative; (18Oct2022) Negative; (20Oct2022) Negative; (22Oct2022) Negative; (24Oct2022) Positive, notes: Tested Positive 24Oct2022. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: It was reported that no other medication in 2 weeks. Patient took Paxlovid for 5 days -11Oct2022 through 16Oct2022. Patient covid-19 test was negative on 16Oct, 18Oct, 20Oct and 22Oct. Patient symptoms returned on 22Oct evening and tested positive on 24Oct2022. No other medical history. Patient had known allergies.
Currently no adverse event reported after 3 hours and 45 minutes.  Vaccine diluted with  1.3 ml instead of 1.8 ml or 38 mcg instead or 30 mcg  dose.
Pt had red rash & flushed on face & chest. Given ZYRTEC 10mg po given. With some relief noted. No further treatment needed. Pt reported improvement.
This spontaneous report as received from a pharmacist refers to a newborn female patient of unknown age. On 08-OCT-2012 17:33, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not provided. Two lot # were involved and the lot # were reported as: 0294AE, expiry date on 06-SEP-2014; and 0395AE, expiry date on 08-NOV-2014. It was unspecified which lot # the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
sudden onset of n/v & moderate h/a 30min p/vax;pt seen 2hr p/vax;pt was entirely well prior to vax;
feeling high; extremely dizzy; could barely stand up; congestion now in chest; massive congestion in her throat; when she coughs it burns; overwhelming nausea; could barely keep food down; chills; feels hot; severe stomach cramping; tried to rest but had to go back to work; threw up; This spontaneous case was reported by a consumer and describes the occurrence of EUPHORIC MOOD (feeling high), DIZZINESS (extremely dizzy), DYSSTASIA (could barely stand up), CHEST DISCOMFORT (congestion now in chest) and OROPHARYNGEAL DISCOMFORT (massive congestion in her throat) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007C2A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19.    On 22-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EUPHORIC MOOD (feeling high), DIZZINESS (extremely dizzy), DYSSTASIA (could barely stand up), CHEST DISCOMFORT (congestion now in chest), OROPHARYNGEAL DISCOMFORT (massive congestion in her throat), COUGH (when she coughs it burns), NAUSEA (overwhelming nausea), VOMITING (could barely keep food down), CHILLS (chills), FEELING HOT (feels hot), ABDOMINAL PAIN UPPER (severe stomach cramping), RESTLESSNESS (tried to rest but had to go back to work) and VOMITING (threw up). At the time of the report, EUPHORIC MOOD (feeling high), DIZZINESS (extremely dizzy), DYSSTASIA (could barely stand up), CHEST DISCOMFORT (congestion now in chest), OROPHARYNGEAL DISCOMFORT (massive congestion in her throat), COUGH (when she coughs it burns), NAUSEA (overwhelming nausea), VOMITING (could barely keep food down), CHILLS (chills), FEELING HOT (feels hot), ABDOMINAL PAIN UPPER (severe stomach cramping), RESTLESSNESS (tried to rest but had to go back to work) and VOMITING (threw up) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment include Mucinex and tried to rest.